Free Trial

Entero Therapeutics (ENTO) Insider Trading & Ownership

$0.67
-0.01 (-1.46%)
(As of 11/4/2024 ET)

Entero Therapeutics (NASDAQ:ENTO) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
0.49%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
2
Amount Of
Insider Selling
(Last 12 Months)
$2,257.90
Get ENTO Insider Trade Alerts

Want to know when executives and insiders are buying or selling Entero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

ENTO Insider Buying and Selling by Quarter

Entero Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/9/2024Sarah RomanoCFOSell476$0.45$214.20  
7/2/2024James SapirsteinCEOSell1,289$1.07$1,379.23  
7/2/2024Sarah RomanoCFOSell621$1.07$664.47  
(Data available from 1/1/2013 forward)

ENTO Insider Trading Activity - Frequently Asked Questions

The list of insiders at Entero Therapeutics includes James Sapirstein, and Sarah Romano. Learn more on insiders at ENTO.

0.49% of Entero Therapeutics stock is owned by insiders. Learn more on ENTO's insider holdings.

The following insiders have sold ENTO shares in the last 24 months: James Sapirstein ($1,379.23), and Sarah Romano ($878.67).

Insiders have sold a total of 2,386 Entero Therapeutics shares in the last 24 months for a total of $2,257.90 sold.

Entero Therapeutics Key Executives

  • Mr. James R. Sapirstein M.B.A. (Age 63)
    R.Ph., CEO & Chairman
    Compensation: $906.2k
  • Dr. Jack A. Syage Ph.D. (Age 69)
    President, COO & Director
  • Ms. Amy Chandler-Skerkis (Age 56)
    Vice President of Regulatory Affairs, QA & Compliance
  • Mr. Martin Krusin M.B.A.
    Senior Vice President of Corporate Development


This page (NASDAQ:ENTO) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners